UK's MRC Technology licenses small molecules to Genentech
This article was originally published in Scrip
Executive Summary
In the first major small-molecule collaboration between the MRC Technology's Centre for Therapeutics Discovery (CTD) and an industry partner, it has exclusively licensed a series of small-molecule drug candidates for the potential treatment of neurological disease to Genentech (Roche).